Maxim Group analyst Allen Klee reiterated a Buy rating on Marpai (MRAI – Research Report) yesterday and set a price target of $6.00. The company’s shares closed yesterday at $1.61.
According to TipRanks, Klee is an analyst with an average return of -18.6% and a 23.77% success rate. Klee covers the Technology sector, focusing on stocks such as Auddia, Zedge, and T Stamp, Inc. Class A.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Marpai with a $6.00 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $13.60 and a one-year low of $1.53. Currently, Marpai has an average volume of 185.2K.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MRAI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marpai Inc operates as a health plan company. It offers a health plan services system that addresses the problems of healthcare past and enables companies to provide healthcare to employees.
Read More on MRAI:
